Major study to track Real-World success of new kidney disease drugs
NCT ID NCT06242327
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or similar antibody drugs. Researchers will track how well the disease responds over time and what factors predict better outcomes. The goal is to understand real-world effectiveness of these advanced treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
ASST HPG23 - Unità di Nefrologia
ACTIVE_NOT_RECRUITINGBergamo, BG, 24127, Italy
-
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
RECRUITINGRanica, BG, 24020, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.